Compass pathways stock forecast.

Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.WebCMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38.WebCompass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore.COMPASS Pathways plc (CMPS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 5.93 -0.05 (-0.84%) At close: 04:00PM EST. 6.03 +0.10 …

... Stock Price Chart Interactive Chart > · Price chart for CMPS. COMPASS Pathways PLC ADR (CMPS) Company Bio. COMPASS Pathways plc operates as a mental health care ...

The consensus 12-month price target for Compass Pathways reflects an upside potential of close to 325%. Even the most pessimistic analyst surveyed by Refinitiv thinks that the stock will double ...Web

CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38. Financial highlights. Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share (including non-cash share-based compensation expense of $4.1 million), compared with $21.2 million or $0.50 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $3.1 million).WebThe average Atai Life Sciences Nv stock price prediction forecasts a potential upside of 1,490.91% from the current ATAI share price of $1.10. What is ATAI's forecast return on equity (ROE) for 2023-2026? (NASDAQ: ATAI) forecast ROE …Shares of Compass Pathways (CMPS 6.61%) have soared since the company's recent stock market debut as support grows for the use of popular recreational drugs to combat depression.COMPASS Pathways PLC Sponsored ADR (CMPS Quick Quote CMPS - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective.Recently, CMPS's ...

COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).

COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83

Real time Compass Pathways Plc (CMPS) stock price quote, stock graph, news & analysis. 3 พ.ค. 2564 ... Did you miss out on being an early investor in the Cannabis Boom? Investing in Compass Pathways stock ($CMPS) may be your golden ticket.About the COMPASS Pathways Plc stock forecast. As of 2023 November 27, Monday current price of CMPS stock is 6.450$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Compass Pathways Plc - ADR stock price has been showing a declining tendency so we believe that similar market …WebCompass Pathways Plc. Market Cap. $399M. Today's Change. (6.61%) $0.40. Current Price. $6.45. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may ...You can buy or sell CMPS and other ETFs, options, and stocks. View the real-time CMPS price chart on Robinhood and decide if you want to buy or sell commission-free. Other fees such as trading (non-commission) fees, Gold subscription fees, wire transfer fees, and paper statement fees may apply. See Robinhood Financial’s fee schedule at rbnhd ...markets.businessinsider.com - August 7 at 4:42 PM. HC Wainwright Reiterates "Buy" Rating for COMPASS Pathways (NASDAQ:CMPS) marketbeat.com - August 4 at 2:37 PM. Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript. finance.yahoo.com - August 4 at 4:00 AM. COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady …Feb 7, 2023 · 3. Compass Pathways. Compass Pathways (CMPS 6.61%) isn't a large holding for Wood. The psychedelic stock makes up less than 1% of her Ark Genomic Revolution ETF's portfolio. However, Compass ...

The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass Pathways PLC.The current Compass Pathways PLC [ CMPS] share price is $6.10. The Score for CMPS is 44, which is 12% below its historic median score of 50, and infers higher risk than normal. CMPS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels. Research COMPASS Pathways' (Nasdaq:CMPS) stock key valuation metrics while comparing it with its industry peers & market side by side. Research COMPASS ... The above table shows the analyst CMPS forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual …The COMPASS Pathways management team will host a conference call at 8.00am ET (1:00pm UK) on August [3], 2023. Please register in advance here to access the call and obtain a local or toll-free phone number and personal pin. A live webcast of the call will be available on COMPASS Pathway’s website at: Second Quarter 2023 Financial …BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways (CMPS – Research Report) yesterday and set a price target of $47.0... BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways (CMPS – Research Rep...

Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

For COMPASS Pathways plc stock forecast for 2023, 2 predictions are offered for each month of 2023 with average COMPASS Pathways plc stock forecast of $5.33, a high forecast of $5.36, and a low forecast of $5.3. The average COMPASS Pathways plc stock forecast 2023 represents a 0.88% increase from the last price of …Web18 ก.ย. 2563 ... Stock Forecast / Price Prediction / Prognosis: Compass Pathways Plc - ADR Forecast. Predictions, Comments & Questions.A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2021, COMPASS Pathways had cash of US$294m and no debt ...WebThese psychedelic stocks are speculative but could potentially offer massive upside. MindMed ( MNMD ): Positioned to rapidly expand its GAD therapy this year. COMPASS Pathways ( CMPS ): COMP360 ...CMPS Stock 12 Months Forecast. Based on 6 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $50.17 with a high forecast of $120.00 and a low forecast of $21.00. The average price target represents a 832.53% change from the last price of $5.38. Nov 27, 2023 · The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ... LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that new positive data demonstrating the potential of COMP360 psilocybin therapy in depression have …What is the current Price Target and Forecast for COMPASS Pathways (CMPS) COMPASS Pathways (CMPS) (Real Time Quote from BATS) $5.93 USD +0.10 …

The average Compass stock price prediction forecasts a potential upside of 35.39% from the current COMP share price of $2.43. What is COMP's forecast return on equity (ROE) for 2023-2026? (NYSE: COMP) forecast ROE is N/A, which is considered weak.Web

1 de jul. de 2023 ... While Compass Pathways' (CMPS 2.17%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by ...

The Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744. Still, if you're looking for an investment, COMPASS Pathways remains the most advanced company in psychedelics in terms of the maturity of its flagship pipeline program. Its psychedelic treatment ...Of course COMPASS Pathways may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying .An in-depth look at the leading psychedelic stocks in the U.S stock market this year. Here’s what you need to know. ... Compass Pathways (NASDAQ:CMPS) $350.9 million Developing one psilocybin ...COMPASS Pathways is a business that is trying to treat a serious form of depression ... Patents, Financials, and Forecast. COMPASS is pre ... COMPASS Pathways is an extremely risky stock, ...CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings data on November 2nd, 2023. The reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted …WebDec 1, 2023 · See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions. It's a gradual path, however, and the stock hasn't moved much overall since the company last provided a financial update on Aug. 11. But in the month of September, Compass shares slid 11.9% ...

COMPASS PATHWAYS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie COMPASS Pathways PLC (spons. ADRs) | A2QCDR | CMPS | US20451W1018 Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ...WebCompass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ... Instagram:https://instagram. 1979 susan b anthony silver dollarbrokerage similar to robinhoodgold trading websiteenbridge inc. stock Still, Compass Pathways stock sank 16% in the stock market today. That's after tumbling 12% on Monday from an eight-month high. Compass also reported financial results for the third quarter. tecs stock pricemoomoo technologies inc View a financial market summary for CMPS including stock price quote, trading volume, volatility, options volume, statistics, and other important company ... ally custodial investment account 6.0%. 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: CMPS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. Volatility Over Time: CMPS's weekly volatility (9%) has been stable over the past year.May 25, 2021 · Learn More. Market Cap. (-2.86%) -$0.17. Current Price. The biotech is developing a treatment paradigm combining talk therapy with a purified version of psilocybin, the active ingredient in "magic ... UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the company’s pivotal Phase III trials, the first-ever Phase III psilocybin therapy trial and the final studies prior to market approval. With the treatment’s …